• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Abbott Laboratories

    4/29/26 4:42:23 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Abbott Laboratories

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    002824100

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    002824100


    1Names of Reporting Persons

    Vanguard Capital Management
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    17,726,843.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    130,676,776.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    130,676,776.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.50 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:   In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Abbott Laboratories
    (b)Address of issuer's principal executive offices:

    100 Abbott Park Road, Abbott Park, IL, 60064
    Item 2. 
    (a)Name of person filing:

    Vanguard Capital Management
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd,, Malvern, PA, 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP Number(s):

    002824100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    130676776
    (b)Percent of class:

    7.5  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    17726843

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    130676776

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Vanguard Capital Management, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Vanguard Capital Management
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:04/29/2026
    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT

    DatePrice TargetRatingAnalyst
    4/22/2026$92.00Outperform → Neutral
    Daiwa Securities
    10/10/2025$145.00Buy
    The Benchmark Company
    7/18/2025$145.00Hold → Buy
    Jefferies
    6/16/2025$143.00Market Perform
    Leerink Partners
    10/8/2024$130.00Outperform
    Oppenheimer
    9/19/2024$131.00Overweight
    Piper Sandler
    7/30/2024Buy → Hold
    Edward Jones
    5/30/2024$121.00Buy
    Goldman
    More analyst ratings

    $ABT
    SEC Filings

    View All

    SEC Form SD filed by Abbott Laboratories

    SD - ABBOTT LABORATORIES (0000001800) (Filer)

    5/27/26 4:47:43 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Abbott Laboratories

    SCHEDULE 13G - ABBOTT LABORATORIES (0000001800) (Subject)

    4/29/26 4:42:23 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Abbott Laboratories

    10-Q - ABBOTT LABORATORIES (0000001800) (Filer)

    4/29/26 4:05:05 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

    First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabetic ketoacidosis, a serious health condition for people with diabetesIntegrates with the Libre digital health ecosystem, allowing people to share glucose and ketone data with caregivers and healthcare providersDesigned for compatibility with leading automated insulin delivery (AID) systemsABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose‑ketone sensing technology for people with

    5/27/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening

    Cologuard® and Cologuard Plus® reaffirmed as preferred options for noninvasive colorectal cancer (CRC) screening in updated American Cancer Society guidelineAbbott to offer only CRC screening portfolio aligned to new ACS recommendations combining preferred stool-based plus additional blood-based optionsRecent publications support Cologuard-first strategy, demonstrating better outcomes for patients, providers, health systems, and payersABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the American Cancer Society (ACS) has released updated colorectal cancer (CRC) screening guidelines that reaffirm Cologuard® and Cologuard Plus® as preferred noninvasive scr

    5/27/26 7:01:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026

    Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remissionNew MRD data from the PARTNER study demonstrate enhanced sensitivity in early triple-negative breast cancerEarly MCED prospective data show low anxiety and minimal psychological burden in real-world useABBOTT PARK, Ill., May 26, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will present 11 abstracts featuring new evidence across the cancer care continuum at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago. The presentations showcase the breadth of Abbott's integrated cancer diagnost

    5/26/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/29/26 5:09:00 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/28/26 8:07:28 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Conroy Kevin T claimed ownership of 131,451 units of Common shares without par value (SEC Form 3)

    3 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/28/26 7:58:34 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Abbott Labs downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Abbott Labs from Outperform to Neutral and set a new price target of $92.00

    4/22/26 7:52:11 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Benchmark Company initiated coverage on Abbott Labs with a new price target

    The Benchmark Company initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $145.00

    10/10/25 8:35:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Labs upgraded by Jefferies with a new price target

    Jefferies upgraded Abbott Labs from Hold to Buy and set a new price target of $145.00

    7/18/25 7:54:43 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Starks Daniel J bought $926,537 worth of Common shares without par value (10,000 units at $92.65) and was granted 2,286 units of Common shares without par value, increasing direct ownership by 0.18% to 6,751,103 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/28/26 7:37:56 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP AND CFO Boudreau Philip P bought $201,300 worth of Common shares without par value (2,200 units at $91.50) (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/27/26 5:34:47 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Leadership Updates

    Live Leadership Updates

    View All

    Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie "The More the Merrier"

    Movie to feature cameos from youth who have overcome significant heart health challenges and are part of the Abbott HeartMates community as well as professional football player and HeartMates ambassador Damar Hamlin "The More the Merrier" is the first Hallmark movie ever to include cameos from real-life individuals who have overcome cardiovascular challengesCharacter in the movie was inspired by Abbott HeartMates member Zeke Mankins, who has established a friendship with Hamlin through Hamlin's ambassador role for the HeartMates communityMovie premieres on Hallmark Channel on Nov. 28, 2025, during Hallmark's Merry Thanksgiving Weekend during "Countdown to Christmas"ABBOTT PARK, Ill., Nov. 4,

    11/4/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

    This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

    5/7/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

    Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

    3/4/25 11:38:00 AM ET
    $ABT
    $TFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $ABT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/13/24 4:55:58 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/23 10:54:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/22 3:15:56 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Financials

    Live finance-specific insights

    View All

    Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

    First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percentCompleted acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncology diagnostics marketAbbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact SciencesABBOTT PARK, Ill., April 16, 2026 /PRNewswire/ -- Abbott today (NYSE:ABT) announced financial results for the first quarter ended March 31, 2026. First-quarter sales increased 7.8 percent on a reported basis and 3.7 percent on a comparable basis.First-quarter GA

    4/16/26 7:30:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott hosts conference call for first-quarter earnings

    ABBOTT PARK, Ill., March 26, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical

    3/26/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott completes acquisition of Exact Sciences

    Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segmentsAdvances Abbott's mission to make healthcare more accessible and give people more control over their healthABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people. "Abbott's global scale, track record of operational and commercial excellence and work with healthcare systems around the world will expand access to important tools for early cancer detection and personalized trea

    3/23/26 8:50:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care